Investor Presentation

January 2023

medmix CONFIDENTIAL

The safe harbor statement under the

US private securities litigation reform act 1995

This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made herein.

Note on Alternative Performance Measures (APM): all bridges from reported figures to APM can be found in the financial review of medmix' midyear report 2022 and all definitions of APM can be found in the APM section of medmix' annual report 2021

medmix CONFIDENTIAL

Overview

medmix CONFIDENTIAL

Medmix in 2021

Global

footprint

~2,000

15*

distribution

Production,

logistics and

employees

sites

25%

CHF

457m

adj. EBITDA

>2.5bn

revenue

margin

~900

Products per year

active patents

5

Note: * as at 31 December 2022

medmix CONFIDENTIAL

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Medmix Ltd. published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 11:39:03 UTC.